A prospectiv, multi-center, non-intervention study of Apatinib in the treatment of advanced gastric cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-15006601

Enrollment

Unknown

Registered

2015-06-11

Start date

2015-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced gastric cancer

Interventions

1:apatinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age: over 18 years old; 2. Pathologically diagnosed with advanced gastric cancer (including adenocarcinoma of the gastroesophageal junction) with measurable metastases outside the stomach (measuring >=10mm on spiral CT scan, satisfying the criteria in RECIST 1.1); 3. Failure of prior therapy (during or after treatment) in patients who have received at least two prior chemotherapy regimens; 4. The patients have indications for treatment and no absolute contraindications for chemotherapy; 5. Patient has to voluntarily join the study and sign the Informed Consent Form for the study.

Exclusion criteria

Exclusion criteria: 1. patients who are allergic to lapatinib or any of the ingredients in lapatinib tablets; 2. Pregnant or lactating women; 3. patients with contraindication; 4. patients who physicians suggest not be included.

Design outcomes

Primary

Measure	Time frame
safety;	—

Countries

China

Contacts

Public ContactFeng Jifeng

Jiangsu Cancer Hospital

fjif@vip.sina.com+86 13901581264

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 23, 2026